# Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

> **NCT03295877** · PHASE1 · COMPLETED · sponsor: **Genentech, Inc.** · enrollment: 28 (actual)

## Conditions studied

- Geographic Atrophy

## Interventions

- **DRUG:** RO7171009

## Key facts

- **NCT ID:** NCT03295877
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-21
- **Primary completion:** 2018-11-20
- **Final completion:** 2018-11-20
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2020-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03295877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03295877, "Safety and Tolerability Study of RO7171009 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03295877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*